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OBJECTIVES The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left
ventricular (LV) structure and function when added to prescribed heart failure therapy.
BACKGROUND The clinical benefit derived from heart failure therapy is attributed to the regression of LV
remodeling.
METHODS At 302 multinational sites, 5,010 patients in New York Heart Association (NYHA)
classification II to IV heart failure taking angiotensin-converting enzyme inhibitor (ACEI)
and/or beta-blocker (BB) were randomized into valsartan and placebo groups and followed
for a mean of 22.4 months. Serial echocardiographic measurements of left ventricular internal
diastolic diameter (LVIDd) and ejection fraction (EF) were recorded. Total study reproduc-
ibility calculated to 90% power at 5% significance defined detectable differences of 0.09 cm for
LVIDd and 0.86% for EF.
RESULTS Baseline LVIDd and EF for valsartan and placebo groups were similar: 3.6  0.5 versus 3.7
 0.5 (cm/m2) and 26.6 7.3 versus 26.9 7.0 (%). Mean group changes from baseline over
time were compared. Significant decrease in LVIDd and increase in EF began by four
months, reached plateau by one year, and persisted to two years in valsartan compared with
placebo patients, irrespective of age, gender, race, etiology, NYHA classification, and
co-treatment therapy. Changes at 18 months were0.12 0.4 versus0.05 0.4 (cm/m2),
p  0.00001 for LVIDd, and 4.5  8.9 versus 3.2  8.6 (%), p  0.00001 for EF. The
exception occurred in patients taking both ACEI and BB as co-treatment, in whom the
decrease in LVIDd and increase in EF were no different between valsartan and placebo
groups.
CONCLUSIONS The Val-HeFT echocardiographic substudy of 5,010 patients with moderate heart failure
demonstrated that valsartan therapy taken with either ACEI or BB reversed LV
remodeling. (J Am Coll Cardiol 2002;40:970–5vi) © 2002 by the American College of
Cardiology Foundation
Recent clinical trials in patients with heart failure have
demonstrated remarkable reductions in mortality and mor-
bidity with the introduction of nitrate and hydralazine,
angiotensin-converting enzyme inhibitors (ACEIs) and
beta-blockers (BBs) (1–4). A common finding has been that
the drugs that exert a favorable effect on outcome also result
in an increase in ejection fraction (EF) or a reduction in left
ventricular (LV) dimension (5–8). This favorable effect on
LV chamber size and function has been attributed to
regression of structural remodeling (9).
Echocardiography has been performed in some trials as a
substudy in a small sample of the overall study population.
Although this strategy has made it possible to identify the
average effect of the agent under study, the limited sample
could only imply a relationship between changes in echo-
cardiographic measurements and outcome, and could not
examine the variability of responses in subgroups of the
population (10–12).
The objectives of the Valsartan in Heart Failure Trial
(Val-HeFT) were to assess the effect of the addition of
valsartan (Novartis Pharma AG, Basel, Switzerland), an
angiotensin receptor blocker (ARB), on mortality and mor-
bidity, and on secondary end points, including signs and
symptoms, quality of life, and neurohormonal and echocar-
diographic variables in patients already receiving standard
therapy, including ACEI and/or BB. The study showed
that all-cause mortality was similar for valsartan and placebo
patients (p  0.801). However, the valsartan group showed
a reduction in combined all-cause mortality and morbidity
compared to placebo (p  0.009). Valsartan patients also
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experienced significant improvements in the symptomatic
and quality of life variables (13). The aims of the echocar-
diographic examination were to evaluate the effect of val-
sartan on left ventricular internal diastolic diameter
(LVIDd) and EF as secondary variables with the entry
criteria of2.9 cm/m2 and40% respectively. With a large
recruitment and echocardiography planned for all patients,
Val-HeFT provided the advantage of examining the effects
of valsartan on ventricular remodeling in the whole popu-
lation as well as in subgroups, including those based on
background drug therapy.
METHODS
In the Val-HeFT echocardiography study, three core labo-
ratories (Los Angeles, Milan, and Stockholm) qualified 291
laboratories based on single and duplicate readings of seven
variables: end-systolic and end-diastolic diameters, lengths,
and volumes; and EF. The measurements were derived from
two-dimensionally directed M-mode recordings from the
parasternal short-axis view, and apical four-chamber view
using the area-length method. Quality of recording was
defined by a scoring system; accuracy of reading, by agree-
ment with core readings; reproducibility, and by agreement
between duplicate studies. After randomization, recording
quality and reading accuracy of the study end points,
LVIDd and EF, were monitored from a random sampling
of studies measured at baseline, 4, 12, and 18 months into
the trial. The qualifying process brought 95% of the sites to
an equivalent level of quality. The monitoring process
showed that recording quality and reading accuracy were
maintained during the trial. From a retrospective power
analysis using the sites’ reproducibility and a population of
4,000 patients to 90% power with a significance level of 5%,
detectable change between treatment and placebo groups at
a single point in time were calculated: the detectable
difference for LVIDd was 0.09 cm and for EF, 0.86%.
Details have been reported in a method paper (14).
Statistical analyses. Measurements of LVIDd and EF
were performed locally at each site and sent to the data
center for analysis. LVIDd/BSA values were obtained by
adjusting LVIDd by each patient’s body surface area (BSA).
Analysis of covariance (ANCOVA) was performed to ana-
lyze change from baseline in LVIDd/BSA and EF at four,
12, 18, and 24 months, and at end point (last post-
randomization observation carried forward). The ANCOVA
model applied included effects for treatment group, pooled
center, baseline value, baseline use of ACEI and/or BB, and
treatment by baseline value interaction. Comparisons be-
tween valsartan and placebo were made for all patients and
within exploratory subgroups categorized by age, gender,
race, and concurrent use of ACEI and BB. Between-
treatment comparisons were based on least-squares treat-
ment group means from the ANCOVA, which were ad-
justed for differences among patients with respect to other
effects in the ANCOVA model. All statistical comparisons
presented are for a significance level of p  0.05. Between-
treatment comparisons of mean change from baseline in
blood pressures and heart rates were made at 4, 12, 18, and
24 months, and at end point using ANCOVA.
RESULTS
Baseline characteristics and demographics have already been
published, and no clinically relevant differences between the
valsartan and placebo groups were found (13,15). Briefly
summarized, the study population was predominantly white
(90%) and averaged 63 years of age, with a male/female
distribution of 4/1. Ninety-eight percent of patients (62%
and 36%, respectively) were in New York Heart Association
(NYHA) functional class II and III, and ischemia was the
etiology of heart failure in 57%. Ninety-three percent of
patients were on ACEI therapy and 35% were on BB
therapy. The echocardiographic baseline measurements and
the distribution of the total population randomized to
valsartan and placebo are summarized in Table 1. Baseline
LVIDd/BSA and EF were generally equivalent for valsartan
and placebo patients, whether considered as a whole or
separated into age, gender, race, etiology, NYHA classifi-
cation, and co-treatment subgroups. This baseline equiva-
lence in EF was also seen between patients taking a BB
alone or with an ACEI (ACEIBB and BBACEI)
and patients not taking a BB (ACEIBB and
BBACEI) ( indicates co-treatment;  indicates not a
co-treatment) . The overall mean  SD baseline LVIDd/
BSA and EF for valsartan patients were 3.6  0.5 cm/m2
and 26.6 7.3%, and for placebo patients, 3.7 0.5 cm/m2
and 26.9  7.0%, respectively.
Figure 1 illustrates the mean changes from baseline in EF
and LVIDd/BSA at four, 12, 18, and 24 months, and at end
point (last available observation after baseline carried for-
ward) for the two treatment groups. A statistically signifi-
cant increase in EF (p  0.00075) and decrease in LVIDd/
BSA (p  0.00002) were observed with valsartan compared
to placebo. With valsartan, EF increased and LVIDd/BSA
decreased from baseline values starting at four months and
persisting throughout the follow-up period for patients
remaining under echocardiographic evaluation. The
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ANCOVA  analysis of covariance
ARB  angiotensin receptor blocker
ANGII  angiotensin II
BB  beta-blocker
EF  ejection fraction
LV  left ventricular
LVIDd  left ventricular internal diastolic diameter
LVIDd/BSA  left ventricular internal diastolic
diameter/body surface area
NYHA  New York Heart Association
RAAS  renin-angiotensin-aldosterone system
Val-HeFT  Valsartan in Heart Failure Trial
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between-treatment differences in mean change from base-
line were statistically significant at all observation periods,
with valsartan providing larger increases in EF and larger
decreases in LVIDd/BSA than placebo. In the placebo
group the increase in EF and decrease in LVIDd progressed
continuously for 24 months.
Figure 2 summarizes the mean changes from baseline to
end point in EF and LVIDd/BSA for valsartan and placebo
Table 1. Baseline LVIDd/BSA and EF*
LVIDd/BSA (cm/m2) EF (%)
V N P N V N P N
All 3.6  0.5 2,511 3.7  0.5 2,499 26.6  7.3 2,509 26.9  7.0 2,499
Age
65 3.6  0.5 1,367 3.6  0.5 1,293 26.5  7.3 1,367 26.6  7.3 1,293
65 3.7  0.5 1,144 3.7  0.5 1,206 26.7  7.2 1,142 27.2  6.8 1,206
Gender
M 3.6  0.5 2,007 3.6  0.5 2,000 26.6  7.2 2,006 27.1  7.0 2,000
F 3.9  0.6 504 3.9  0.6 499 26.6  7.6 503 26.0  7.1 499
Race
White 3.7  0.5 2,255 3.7  0.5 2,271 26.9  7.2 2,253 27.0  7.0 2,271
Black 3.6  0.5 182 3.6  0.5 162 24.3  7.5 182 26.0  7.5 162
Oriental/other 3.8  0.5 74 3.9  0.6 66 22.5  7.3 74 24.2  7.5 66
Etiology
Ischemic 3.6  0.5 1,446 3.6  0.5 1,419 27.2  7.2 1,444 27.4  6.9 1,419
Non-ischemic 3.7  0.6 1,065 3.7  0.6 1,080 25.8  7.3 1,065 26.2  7.2 1,080
NYHA class
I–II 3.6  0.5 1,562 3.6  0.5 1,538 27.4  7.0 1,560 27.6  7.0 1,538
III–IV 3.7  0.6 949 3.7  0.5 961 25.2  7.4 949 25.7  7.0 961
Subgroup†
ACEIBB 3.6  0.5 794 3.6  0.5 816 27.2  7.3 794 27.2  7.4 816
ACEIBB 3.7  0.5 1,532 3.7  0.5 1,502 26.2  7.3 1,532 26.5  6.9 1,502
BBACEI 3.6  0.5 73 3.6  0.6 67 28.5  7.1 71 28.9  7.0 67
BBACEI 3.7  0.5 112 3.7  0.6 114 27.1  6.4 112 28.6  6.4 114
*The entries are mean  SD. The varying N between V and P, and between LVIDd/BSA and EF were determined by the data
available for the analyses. †Under subgroup,  designates co-treatment,  designates not a co-treatment.
ACEI  angiotensin-converting enzyme inhibitor; BB  beta blocker; EF  ejection fraction; LVIDd/BSA  left
ventricular internal diastolic diameter/body surface area; N  number of patients; NYHA  New York Heart Association; P 
placebo; V  valsartan.
Figure 1. Effects of valsartan on left ventricular internal diastolic diameter/body surface area (LVIDd/BSA) and ejection fraction (EF) compared to placebo:
change from baseline to month of observation. The histobars represent mean changes (adjusted for effects for treatment group, pooled center, baseline value,
baseline use of angiotensin-converting enzyme inhibitor or beta blocker, and treatment by baseline value interaction by analysis of covariance) between
baseline values and those at months 4, 12, 18, 24, and at end point (last observation available carried forward) for valsartan (black bars) and placebo (white
bars). Baseline values at each observation period are adjusted for the number of patients with available data. Change is expressed in absolute units for EF
(%) and LVIDd/BSA (cm/m2). The p values for the between-treatment comparison are determined from least-squares mean change.
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patients by co-treatment subgroups, ACEIBB,
ACEIBB, BBACEI, and BBACEI with ad-
justments by ANCOVA. In every group, except those
patients taking both ACEI and BB, valsartan produced a
rise in EF and a reduction in LVIDd/BSA of significance
compared to placebo, with the exception of EF in the
relatively small BBACEI group (n  102) in which the
1.3% unit greater increase in the valsartan group did not
reach statistical significance. In the patients taking both
co-treatments, valsartan did not produce further improve-
ment in EF and LVIDd/BSA.
Systolic blood pressure was reduced by a greater extent
with valsartan than placebo,5.2 15.8 (mean SD) mm
Hg versus 1.2  14.8 at four months (p  0.0001), and
5.2  16.0 mm Hg versus 1.3  15.9 at one year (p 
0.0001). Valsartan slowed heart rate by 0.3 to 0.8 beats/min
more than placebo, with statistically significant differences
at month 4 (p  0.005) and 12 (p  0.05).
DISCUSSION
The objective of the Val-HeFT echocardiographic exami-
nation was to study the effects of valsartan treatment on
LVIDd and EF as secondary outcomes. The results from
serial echocardiograms recorded and read locally on 5,010
patients were conclusive: diastolic dimension is reduced and
systolic function is improved, both being statistically signif-
icant in the group of patients receiving valsartan in addition
to their prescribed treatment compared to placebo. Because
all of the patients were studied echocardiographically, the
relationship between outcomes and LV structure and func-
tion was confirmed. In addition, the large volume of studies
provided sufficient data to track the relationship between
outcomes and LV remodeling in subgroups of patients. The
most notable subgroup differences emerged in those treated
with different background neurohormonal-inhibiting ther-
apy (13).
In the subgroups treated with either ACEI or BB, or
neither, valsartan demonstrated significant baseline-to-end
point changes for EF and LVIDd compared to placebo. As
previously reported (13), these subgroups exhibited a favor-
able effect of valsartan on combined morbidity-mortality,
and a trend for a benefit on mortality. Valsartan produced
similar benefit on remodeling and outcomes in the subgroup
not taking ACEI, with or without BB, despite the small
population of less than 10% of the total recruitment (Fig. 2).
In distinct contrast, in the subgroup treated with both
ACEI and BB, valsartan showed no effect on LV remod-
eling and, as previously reported, showed a trend for an
adverse effect on morbidity and mortality.
Background therapy probably played a role in the unusu-
ally positive placebo effect on LVIDd and EF. The sus-
tained two-year decrease in LV diameter and increase in LV
emptying may reflect a delayed response to co-treatment,
particularly to BB, which require several months to achieve
maximum change in LV remodeling and function (16).
Both the design of the study, which mandated stability of
background treatment for only two to four weeks, and the
baseline findings, which found patients taking BB and not
taking BB to have equivalent EF and LVIDd, corroborate a
delayed response to co-treatment in the placebo group.
The mechanism of the favorable effect of valsartan on
outcome and LV remodeling must remain conjectural;
Figure 2. Effects of valsartan on left ventricular internal diastolic diameter/body surface area (LVIDd/BSA) and ejection fraction (EF) compared to placebo
by co-treatment group: change from baseline to end point. The histobars represent mean changes (adjusted for effects for treatment group, pooled center,
baseline value, baseline use of angiotensin-converting enzyme inhibitor [ACEI] and/or beta-blocker [BB], and treatment-by-baseline value interaction by
analysis of covariance) between baseline values and those at end point (last observation available carried forward) for co-treatment subgroups randomized
to valsartan (black bars) and placebo (white bars) groups. Baseline values at each observation period are adjusted for the number of patients with available
end point data. Change is expressed in absolute units for EF (%) and LVIDd/BSA (cm/m2). The p values for the valsartan versus placebo comparison are
determined from least-squares mean change. Subgroups are designated by ()  co-treatment and ()  not a co-treatment with ACEI and BB.
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however, the results suggest that angiotensin II (ANGII)
contributes to the progression of heart failure even in
patients treated with ACEI and BB, both of which act to
inhibit the renin-angiotensin-aldosterone system (RAAS).
Because ANGII is formed by angiotensin-converting en-
zyme and non–angiotensin-converting enzyme pathways,
distal blockade with an ARB provides more complete
blockade of the RAAS (17). Although ANGII acts at
multiple sites, a plausible mechanism of valsartan action is
on ANGII that directly affects the structural abnormalities
in the left ventricle by its known mitogenic effect (18–20).
As valsartan also lowered systolic blood pressure by an
average of 5 mm Hg, afterload reduction cannot be excluded
as a factor in the anti-remodeling result. The experience
with vasodilators is mixed, with prazosin producing a
sustained blood pressure fall without improving EF (21),
and felodipine lowering blood pressure and increasing EF
from the same LVIDd (22). Nevertheless, ANGII is ubiq-
uitous and any proposed mechanism for ARB reversing
remodeling becomes inferential.
Val-HeFT provided convincing evidence that additional
inhibition of the RAAS with an ARB in heart failure can
improve LV structure and function beyond that affected by
prescribed therapy, including ACEI or BB alone. Val-
HeFT also demonstrated that given the low annual mortal-
ity of 9% in the placebo subgroup taking prescribed treat-
ment, it is unlikely that future trials can target mortality as
a primary end point. The link between the echocardio-
graphic results and a benefit on the morbidity-mortality end
point strongly supports regression of LV remodeling as a
surrogate marker for a favorable prognosis, for future design
of clinical trials, and for guiding efficacy of heart failure
therapy.
Conclusions. The benefit on outcome in Val-HeFT was
accompanied by echocardiographic evidence for regression
of LV remodeling. The background therapy subgroup that
had an unfavorable outcome had no effect on remodeling.
The trial results further illustrate the usefulness of monitor-
ing structural changes in the left ventricle as a guide to
long-term efficacy in heart failure treatment.
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APPENDIX
The Val-HeFT Investigators and Echocardiography Staff
included the following: UNITED STATES: ALABAMA:
BIRMINGHAM—University of Alabama: R. Bourge,
M. F. Aaron, R. L. Benza, B. A. Foley, B. K. Rayburn, G.
Perry; University of Alabama Hypertension Program: S.
Oparil, D. A. Calhoun, L. J. Dell’Italia, G. Perry, C.
Scott-Mays, M. Huelett; Veterans Affairs Medical Center:
G. J. Perry, L. Lowe, C. Scott-Mays, M. Huelett; ARI-
ZONA: GILBERT—Advanced Cardiac Specialists: R. Sie-
gel, A. W. Nuttall, B. Barker, M. Chuang, P. L. Under-
wood, A. Bhaskaran, S. Goodman; SCOTTSDALE—
Mayo Clinic Scottsdale: R. W. Lee, H. Loutfi, B. Beilby;
TUCSON—Arizona Clinical Research Center: J. E. Bou-
let, M. A. Adamczyk, L. D. Lancaster, M. C. Morales, B.
Dwyer; University of Arizona Heart Center: P. Fenster, K.
Kern, L. Foster, N. Cosgrove; Veterans Affairs Medical
Center: J. Christensen, D. Shocken, J. R. Parks III, P.
Perry, A. Bastian, D. Irons, M. Pigman; CALIFORNIA:
CARMICHAEL—Capital Interventional Cardiology:
J. Hemphill, S. Baron, D. Fisher, E. Silva; ENCINITAS—
San Diego Cardiovascular Associates: G. Dennish, J. W.
Myers, J. R. Backman, J. A. Bonanno, M. L. Charlat,
D. M. Hill, D. A. Goodman, L. Eastwood, A. Burns, J.
Myers, D. Moser, L. Donaghey; ESCONDIDO—
Escondido Cardiology Associates, Inc: J. Gorwit, J. H.
Detwiler, C. R. Gilbert, D. Mulvihill, D. R. Leahy, R. J.
Acheatel, G. Herrara, P. Scott; Palomar Medical Group:
R. M. Stein, E. W. Lee, J. J. Lilley, B. W. Meyerhoff,
E. A. P. Salada, M. H. Shapiro, J. D. Wolosin, G. Herrara,
P. Scott; FRESNO—Veterans Affairs Medical Center:
P. C. Deedwania, E. Carbajal, A. Monges; LA JOLLA—
Scripps Clinic: D. Costello, H. H. Shively, N. Dalton; LA
MESA—Cardiology Medical Group of San Diego: L. W.
Sprinkle, M. J. McGreevy, R. K. Goldberg, S. Gerry, S.
Sullivan; LARKSPUR—Cardiology Associates of Marin
and San Francisco: J. Sklar, J. Adamn, K. Gershengorn, G.
Jacobs, A. Kao, E. Shafton, D. Sperling, B. Strunk, M.
Wexman, J. Young, W. R. Budge, J. O’Connor; LOMA
LINDA—Jerry L. Pettis Veterans Affairs Medical Center:
J. T. Heywood, G. Frivold, L. Stoletniy, G. Pauls, P.
Applegate, G. Pauls, H Lo; LOS ANGELES—Cedars
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Mezei; DEBRECEN—Medical University of Debrecen: I.
E´des, F. Tibor, P. Erzse´bet, SZEGED—Zul Department
Medicine University: M. Csana´dy, T. Foster; ITALY: AN-
CONA—Ospedale Regionale “Lancisi”: R. Mocchegiani,
L. Pasetti, A. Budini; BENTIVOGLIO—Ente Osped-
aliero: G. Di Pasquale, E. Cere`; BOLOGNA—Policlinico
Universitario “S. Orsola-Malpighi”: A. Branzi, C. Rapezzi,
P. Vassallo, C. Manes; CAGLIARI—Ospedale “San
Michele Brotzu”: A. Sanna, M. Porcu, M. G. Panzuto,
CASARANO—Presidio Ospedaliero “F. Ferrari”: G. Pet-
tinati, F. De Santis; CASERTA—Azienda Ospedaliera -
Ospedale Civile: G. Corsini, A. Vetrano, M. Catanzaro;
CASSANO D’ADDA—Ospedale di Circolo Zappatoni:
G. Gibelli, G. Castiglioni, M. Ferrari; CATANZARO—
Policlinico “Mater Domini”: F. Perticone, G. Ventura, F.
Giancotti, C. Cosco; CIVITANOVA MARCHE—
Presidio Ospedaliero: C. Massacci, A. Fraticelli, P. Dome-
nella; COMO—Ospedale “Sant’Anna”: G. Ferrari, R. Bel-
luschi, E. Butti, F. Ruffa; COSENZA—Ospedale Civile
dell’Annunziata: F. Plastina, G. Misuraca, O. Serafini, R.
Caporale; CUNEO—Ospedale “Santa Croce”: E. Uslenghi,
A. Deorsola, F. Margaria; DESIO—Ospedale Provinciale:
G. Foti, S. Gramenzi; GUSSAGO—Fondazione “S.
Maugeri”-Clinica del Lavoro: A. Giordano, S. Scalvini, E.
Zanelli, M. Campana; MAGENTA—Ospedale Civile
“Fornaroli”: A. Formentini, A. Cavalli, M. Tusa; MESA-
GNE—Ospedale “San Camillo”: V. Santoro, G. Giorda, R.
Giaccari; MONTESCANO—Fondazione “S. Maugeri”-
Clinica del Lavoro: F. Cobelli, S. Capomolla, E. Traversi,
M. Granchini; PADOVA—Azienda Ospedaliera: S. Dalla
Volta, L. Cacciavillani, G. M. Boffa, V. Patrizia; PAL-
ERMO—Presidio Ospedaliero “Villa Sofia”: A. Battaglia,
V. Cirrincione, F. Ingrillı`, M. Di Francesco; PAL-
ERMO—Ospedale “Buccheri La Ferla- Fatebenefratelli”:
A. Castello, A. M. Schillaci, A. Taormina, G. Americo;
PASSIRANA-RHO—Ospedale Civile: C. Schweiger, F.
Rusconi, M. Palvarini, I. Belloni; PAVIA—Ospedale Poli-
clinico “San Matteo”: L. Tavazzi, A. Gavazzi, C. Campana,
C. Inserra, C. Opasich; PERUGIA—Ospedale Policlinico
“Monteluce”: G. Alunni, E. Bosi, R. Panciarola, . K Savino;
PERUGIA—Ospedale “ R. Silvestrini”: C. Porcellati, M.
Del Pinto, P. Verdecchia; PIAZZA ARMERINA—
Ospedale Nuovo: B. Aloisi, M. Farruggio; ROMA—
Ospedale “San Camillo”-Forlanini-Cesalpino: P. Tanzi, F.
Pozzar, S. Petrolati,; ROMA—Ospedale “San Filippo
Neri”: M. Santini, G. Ansalone, P. Giannantoni; ROMA—
Ospedale “San Camillo”: E. Giovannini, I. Bisceglia, G.
Minardi; ROMA—Ospedale “Santo Spirito”: V. Ceci, N.
Aspromonte, A. Sestili; SAN PIETRO VERNOTICO—
Ospedale “N. Melli”: A. Renna, S. Pede, C. Pico; SAR-
ZANA—Ospedale “San Bartolomeo”: G. Filorizzo D. Ber-
toli, L. Magliani; SONDALO—Ospedale “E. Morelli”: G.
Occhi, N. Partesana, P. Bandini; TERMOLI—Ospedale
“San Timoteo”: D. Staniscia, M. Olivier; TRADATE—
Presidio Ospedaliero “L. Galmarini”: G. Poggio, S. Lom-
broso, M. Bignotti; TRADATE—Fondazione “S.
Maugeri”–Clinica del Lavoro: R. Pedretti, C. Anza`, A.
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Laporta, F. Santoro; TRICASE—Ospedale “Cardinale Pa-
nico”: A. Galati, R. Mangia, A. P. Morciano; TRIESTE—
Ospedale Maggiore: G. Sinagra, F. Longaro, I. Tavcar, B.
Pinamonti; UDINE—Azienda Ospedale “S. Maria della
Misericordia”: P. Fioretti, M. C. Albanese, C. Fresco, A. L.
Cuzzato, L. Del Mostre; VERUNO—Fondazione Clinica
del Lavoro “Salvatore Maugeri”: P. Giannuzzi, U. Corra`, F.
Scapellato; VILLAFRANCA—Ente Ospedaliero: G. P.
Perini, K. Ghebremarian-Tesfau; NORWAY: BERGEN—
Cardiologklinik: S. Toft; BODOE—Bodoe: K. T. Lappe-
ga˚rd; OSLO—Ullevaal Hospital: A. Westheim, T. de
Klemsdal, M. Bjorstro˜n, S. Solheim, S. Stavnes;
STAVANGER—Hjertelaget: K. Dickstein V. Thuseth, A.
Heruold, V. Bonarjee; TO¨NSBERG—Vestfold Central
Hospital: K. Knutsen, G. Fro¨land, J. E. Otterstad; SOUTH
AFRICA: CAPETOWN—Tygerberg Hospital: L. J. Bur-
gess, A. Doubell, H. Prozesky, M. M. Pretorius; Groote
Schuur Hospital: P. Commerford, J. E. Stevens;
DURBAN—King Edward VIII Hospital: D. P. Naidoo;
JOHANNESBURG—Johannesburg General Hospital: P.
Manga, E. Klug, D. Smith; SPAIN: BARCELONA—
Hospital de la Santa Cruz y San Pablo: A. Bayes de Luna,
A. Martinez Rubio, A. Aguilar Llodis, V. Pen˜a Forcada, G.
Pons Llado; BARCELONA—Hospital de Valle Hebro´n:
E. Galve Basilio, A. Mallol, E. Nieto Santa, A. Evangelista;
BARCELONA—Hospital Clinico y Provincial de Barce-
lona: E. Roig, M. Cardona, F. Perez Villa, C. Pare´, M.
Azqueta, M. Velamazan; BARCELONA—Hospital Cruz
Roja de Barcelona: P. Dalmau Jaime, M. Gomez Gerboles,
I. Gomez Collado, J. L. Sobrepera; CASTELLOˆN—
Hospital General de Castello´n: J. L. Diago Torrent, C.
Guallar, J. Moreno, J. L. Diez; CORDOBA—Hospital
Reina Sofia: F. Valles Belsue; GIRONA—Hospital Uni-
versitari de Girona Doctor Josep Trueta: R. Masia Mar-
torell, X. Albert, M. J. Perez Ayuso; HOSPITALET DE
LLOBREGAT-BARCELONA—Hospital de la Cruz
Roja de Hospitalet: J. Gibergans Jorge, O. Guri Baiget,
E. H. Espinach; HOSPITALET DE LLOBREGAT-
BARCELONA—Hospital Principes de Espaa˜-Ciutat Sa-
nit. de Bellvitge: N. Manito Lorite, J. Roca Elias, C.
Ugartemendia Uranga; LEON—Complejo Hospitalario de
Leo`n: J Bayo´n Fernandez, I Iglesias; MADRID—Hospital
Ramon y Cajal: E. Asin Cardiel, V. Barrios, A. Garcia
C a s t r o , C . P a s c u a l ; S A N T I A G O D E
COMPOSTELA-LA CORUN˜A—Hospital General de
Santiago de Compostela: M. Gil de la Pen˜a; SWEDEN:
BORAS—Medicinska kliniken: C. Wettervik, H. Ty-
gersen, P. Svenningsson; EKSJO¨ - Medicinska kliniken: S.
Ekdahl, S. Hansen, C. Ho¨glund, G. Lindholm; GO¨TE-
BORG—Sahlgrenska sjuhuset: B. Karlsson, J. Herlitz, A.
Samuelsson; HELSINGBORG—Medicinska kliniken: P.
Katzman, L. Ljungdahl, G. de Pedis, O. Fredholm;
SANDVIKEN—Medicinska kliniken: J. Ellstro¨m, H.
Brodersson; STOCKHOLM—Stockholm Heart Center:
C. Ho¨glund, L. Hjelmaeus, L Nygren; THE NETHER-
LANDS: AMERSFOORT—Ziekenhuis Eemland (Loka-
tie De Lichtenberg): B. J. B. Hamer, M. J. M. Cramer, W.
Van Koedk; AMSTERDAM—St. Lucas Ziekenhuis: A. R.
Willems, W. G. de Voogt, J. Visser, A. Folhers; AM-
STERDAM—Onze Lieve Vrouwe Gasthuis: G. J. Laar-
man, U. D. Heyden, T. Slagbroom; ARNHEM—
Ziekenhuis Rijnstate: L. H. J. Van Kempen, W. M.
Sieswerdo-Mesman, A. M. de Gier, F. F. Willems; BEN-
NEKOM—Ziekenhuis Gelderse Vallei: F. R. den Hartog,
H. J. Schaapma, T. Veldhuis; BREDA—Ignatius Zieken-
huis: P. H. J. M. Dunselman, M. R. P. Baselier; DELFT—
Reinier de Graafgasthuis: A. J. A. M. Withagen, D. P. W.
Beelen, M. C. Jaleer, I. Nyenhuis de Ruiter; DE-
VENTER—St. Deventer Ziekenhuizen: H. Groeneveld,
D. J. A. Lok, P. W. F. Bruggink, A. de la Porte, E. A.
Badings, J. S. Kalfsterman-Lammertink; DOR-
DRECHT—Drechtsteden Ziekenhuis/Lokatie Refaja: Ph.
W. Fels, I. Stoel, R. Campfens; DORDRECHT—
Merwede Ziekenhuis: P. N. W. M. Breuls, H. Jausen;
EINDHOVEN—Catharina Ziekenhuis: H. R. Michels,
D. Groot, C. Peels; ENSCHEDE—Medisch Spectrum
Twente: P. H. van den Burgh, J. van Es, R. Binnenmars, B.
Zinger; GOES—Oosterscheldeziekenhuis: A. H. Liem, R.
v Lennep, J. A. J. de Boo, E. Bruyns; GORINCHEM—
Beatrixziekenhuis: P. van Rossum, M. Bos, M. Suylekom;
GRONINGEN—Martini Ziekenhuis: P. J. L. M. Bernink,
J. L. Posma, A. Kloppenberg-Oly, H. Groen; HEEMST-
EDE—Spaarne Ziekenhuis: J. C. L. Wesdorp, M. Bruns;
HEERLEN—Ziekenhuis De Wever en Gregorius: J. A.
Kragten, J. de Warizimont-Henquet, R. Feld, J. Ritzen, J.
Kremer, S. Gielen, G. Wy¨nantsl, H. van den Burgt;
TERNEUZEN—Ziekenhuis Zeeuws-Vlaanderen:
G. M. G. Paulussen, R. J. P. Taverne, R. van den Bosche,
M. Piefeks; TILBURG—St. Elisabeth Ziekenhuis: N. J.
Holwerda, R. van Rijswijk, W. Wonnink; Maria Zieken-
huis (Tweesteden Ziekenhuis): P. C. J. M. Lindner, H. v
Kesteren, A. Vet, J. Widdershoven, T. Maes, H. Baars;
VELDHOVEN—St. Joseph Ziekenhuis: L. C. Slegers, M.
Beganovic, J. Snegers, H. Schaffers. UNITED KING-
DOM: NORTH IRELAND, BELFAST—Belfast City
Hospital: G. D. Johnston, H. Hale; Royal Victoria Hospi-
t a l : P . N i c h o l l s , H . O n g , K . M o r r i s o n ;
BOURNEMOUTH—Royal Bournemouth Hospital: A.
Rozkovec, C. Cope, A. Whiting, D. Maybe, C. Chase;
BRISTOL—Bristol Royal Infirmary: T. R. Cripps, H.
Portch, P. Kelly; CAMBRIDGE—Papworth Hospital: L.
Shapiro, C. Wisbey; HARROW—Northwick Park Hospi-
tal: D. Lubel, S. J. Chugh; LEEDS—Yorkshire Heart
Center: L. B. Tan, S. Williams, G. Wharton, S. Sleight, J.
Foster; LEICESTER—Leicester Royal Infirmary: I.
Squire, D. Barnett, A. McCullough; The Glenfield Hospi-
tal, P. J. B. Hubner, S. Gupta, S. Waterfield; LINDLEY-
HUDDERSFIELD—Huddersfield Royal Infirmary: R. N.
Stevenson, C. Welsh; LIVERPOOL—Broadgeen Cardio-
thoracic Centre: D. Connelly, M. Jackson, K. Robotham;
LONDON—Charing Cross Hospital: A. Coats, J. S. R.
Gibbs, G. Badahl,; MANCHESTER—Wythanshawe
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Hospital: R. Levy, J. Hokney, S. Souttern, D. Tayler;
MIDDLESEX—Ealing Hospital: J. S. Kooner, C. Mc-
Carthy; Isle of Wight, NEWPORT—St. Mary’s Hospital:
A. Baksi, Z. Thomas, C. Elliott; ROTHERHAM-
SOUTH YORKSHIRE—Rotherham District General
Hospital: M. L. K. Ghosh, O. Otaiku, P. Spencer, D.
Dransfield; TELFORD-SHROPSHIRE—The Princess
Royal Hospital: M. E. Heber, L. Dixon, K. Nicholas.
EXECUTIVE COMMITEE: Jay N. Cohn, MD (Study
Chairman), Susan Ziesche, RN (National Study Coordina-
tor for the U.S.), Tara Bonde (Secretary), Nina Lacis
(Secretary); Study Co-Chairman’s Office (Milan)—Gianni
Tognoni, MD (Study Co-Chairman), Roberto Latini, MD,
Aldo Maggioni, MD (Study Coordinators for non-U.S.
centers); Echocardiographic Core Laboratories—Maylene
Wong, MD (Los Angeles), Lidia Staszewsky, MD, Alberto
Volpi, MD, Roberto Latini, MD, Giuseppina Di Bitetto,
Elena Pozzoli (Milan), Christer Ho¨glund, MD, PhD,
Lisbeth Nygren (Stockholm); Data Management and Anal-
ysis—Enrico Nicolis, MS, Eugenio Santoro, MS, Francesco
Livraghi, MS, Simona Barlera, MS, Paolo Capello, BS,
Giuseppe Andreoni, PhD (Milan).
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